(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -7.76%173.78B | -17.41%110.72B | -26.14%48.96B | -22.65%225.07B | -17.23%188.4B | -15.66%134.06B | -17.60%66.28B | -2.64%290.99B | 16.77%227.62B | 31.57%158.96B |
Operating income | -7.76%173.78B | -17.41%110.72B | -26.14%48.96B | -22.65%225.07B | -17.23%188.4B | -15.66%134.06B | -17.60%66.28B | -2.64%290.99B | 16.77%227.62B | 31.57%158.96B |
Cost of sales | ---- | 24.39%-92.29B | ---- | 23.95%-197.5B | ---- | 13.06%-122.06B | ---- | 1.69%-259.7B | ---- | -29.33%-140.4B |
Operating expenses | 11.82%-147.31B | 24.39%-92.29B | 31.20%-41.44B | 23.95%-197.5B | 16.88%-167.06B | 13.06%-122.06B | 16.90%-60.24B | 1.69%-259.7B | -16.01%-200.98B | -29.33%-140.4B |
Gross profit | 24.00%26.47B | 53.50%18.43B | 24.28%7.51B | -11.87%27.57B | -19.88%21.34B | -35.32%12.01B | -23.95%6.04B | -9.89%31.28B | 22.82%26.64B | 51.37%18.56B |
Selling expenses | 6.53%-305M | ---- | 6.07%-90.57M | ---- | -21.52%-326.29M | ---- | 0.14%-96.43M | ---- | -20.17%-268.51M | ---- |
Administrative expenses | -20.15%-3.43B | -21.80%-3.3B | -9.15%-1B | 1.82%-5.9B | 2.74%-2.85B | 7.30%-2.71B | 0.62%-920.06M | 5.02%-6.01B | -7.98%-2.93B | -23.79%-2.92B |
Research and development expenses | 25.39%-2.49B | -0.03%-1.69B | -24.86%-574.18M | 22.39%-3.73B | -22.63%-3.33B | -1.35%-1.69B | -9.80%-459.85M | -98.77%-4.81B | -123.95%-2.72B | -153.49%-1.67B |
Profit from asset sales | 261.00%18.52M | ---- | 4,269.66%16.56M | ---- | -96.26%5.13M | ---- | 102.14%379K | ---- | 326.19%137.13M | ---- |
Revaluation surplus | 50.82%-41.36M | ---- | -1,630,300.00%-16.3M | ---- | -253.21%-84.1M | ---- | -100.00%1K | ---- | 202.18%54.89M | ---- |
-Changes in the fair value of other assets | 50.82%-41.36M | ---- | -1,630,300.00%-16.3M | ---- | -253.21%-84.1M | ---- | -100.00%1K | ---- | 202.18%54.89M | ---- |
Impairment and provision | -170.61%-63.24M | -105.89%-13.74M | 40.09%-24.29M | 89.27%-451.89M | 102.85%89.56M | 110.84%233.12M | 74.04%-40.54M | 22.84%-4.21B | -61.02%-3.15B | -350.02%-2.15B |
-Impairment of property, machinery and equipment | ---- | ---2K | ---- | 84.25%-597.64M | ---- | ---- | ---- | 6.62%-3.8B | ---- | ---2.1B |
-Other impairment is provision | -170.61%-63.24M | -105.89%-13.74M | 40.09%-24.29M | 135.19%145.75M | 102.85%89.56M | 562.55%233.12M | 74.04%-40.54M | 70.22%-414.14M | -61.02%-3.15B | 89.46%-50.4M |
Special items of operating profit | 171.13%1.56B | 115.67%527.63M | 36.48%343.81M | 15.98%153.37M | 60.93%575.35M | 16.65%244.65M | 844.60%251.91M | 107.14%132.24M | 234.95%357.52M | 119.29%209.73M |
Operating profit | 45.18%19.51B | 72.59%13.95B | 29.71%5.44B | 7.63%17.64B | -15.74%13.44B | -32.81%8.09B | -24.84%4.2B | -12.18%16.39B | 16.26%15.95B | 59.46%12.03B |
Financing income | ---- | 86.64%299.73M | ---- | -17.18%395.18M | ---- | -24.99%160.59M | ---- | 53.37%477.14M | ---- | 95.43%214.09M |
Financing cost | 5.96%-2.11B | 2.50%-1.6B | 14.68%-697.46M | 14.28%-3.34B | 12.76%-2.24B | 17.59%-1.64B | 17.10%-817.42M | 14.07%-3.89B | 9.38%-2.57B | 1.90%-1.99B |
Share of profits of associates | ---- | 201.18%104.28M | ---- | 53.84%200.97M | ---- | 142.53%34.62M | ---- | 130.86%130.63M | ---- | -122.89%-81.41M |
Share of profit from joint venture company | ---- | 168.04%208.32M | ---- | 6.14%189.89M | ---- | -6.27%77.72M | ---- | 9.02%178.91M | ---- | 11.71%82.92M |
Special items of earning before tax | 191.58%132.08M | ---- | -32.09%47.04M | ---- | 33.70%-144.22M | ---- | 198.57%69.26M | ---76M | 72.16%-217.51M | ---- |
Adjustment items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1K | ---- |
Earning before tax | 58.61%17.54B | 93.00%12.97B | 38.99%4.79B | 14.24%15.09B | -16.02%11.06B | -34.51%6.72B | -23.83%3.45B | -6.89%13.21B | 30.27%13.17B | 69.34%10.26B |
Tax | -35.31%-2.51B | -48.19%-1.68B | -36.01%-743.46M | -5.97%-2.51B | 14.15%-1.86B | 27.11%-1.13B | 36.61%-546.62M | 17.57%-2.37B | -7.17%-2.16B | -24.68%-1.55B |
After-tax profit from continuing operations | 63.32%15.03B | 102.09%11.29B | 39.55%4.05B | 16.05%12.58B | -16.39%9.2B | -35.83%5.59B | -20.82%2.9B | -4.18%10.84B | 36.04%11B | 80.92%8.71B |
Special items of earning after tax | ---1K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Adjustment items of earning after tax | --1K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Earning after tax | 63.32%15.03B | 102.09%11.29B | 39.55%4.05B | 16.05%12.58B | -16.39%9.2B | -35.83%5.59B | -20.82%2.9B | -4.18%10.84B | 36.04%11B | 80.92%8.71B |
Minority profit | 56.17%6.01B | 96.95%4.27B | 67.10%1.82B | -11.80%5.87B | -31.35%3.85B | -48.95%2.17B | -34.23%1.09B | 19.68%6.65B | 101.53%5.61B | 147.38%4.25B |
Profit attributable to shareholders | 68.46%9.02B | 105.36%7.02B | 23.01%2.23B | 60.23%6.72B | -0.85%5.35B | -23.32%3.42B | -9.78%1.81B | -27.21%4.19B | 1.72%5.4B | 44.01%4.46B |
Basic earnings per share | 69.90%0.525 | 106.57%0.409 | 23.81%0.13 | 63.60%0.391 | -0.32%0.309 | -23.55%0.198 | -9.48%0.105 | -26.69%0.239 | 2.31%0.31 | 47.16%0.259 |
Diluted earnings per share | 69.58%0.524 | 106.06%0.408 | 23.81%0.13 | 63.18%0.39 | -0.32%0.309 | -23.55%0.198 | -9.48%0.105 | -26.69%0.239 | 2.31%0.31 | 47.16%0.259 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data